GNRH1 and ovarian hyperstimulation syndrome: A recent systematic review of RCTs with meta-analysis detected in our search showed no difference in OHSS risk in patients who received, GnRH agonist as luteal phase support compared to progesterone (2 RCTs; RR 0.96; 95% CI 0.32 to 2.89, n = 523; I2 = 0%) [120].